IN2014DN08721A - - Google Patents
Info
- Publication number
- IN2014DN08721A IN2014DN08721A IN8721DEN2014A IN2014DN08721A IN 2014DN08721 A IN2014DN08721 A IN 2014DN08721A IN 8721DEN2014 A IN8721DEN2014 A IN 8721DEN2014A IN 2014DN08721 A IN2014DN08721 A IN 2014DN08721A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- present
- regions
- modified
- contain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639729P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038538 WO2013163630A1 (en) | 2012-04-27 | 2013-04-26 | Modified antibody regions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08721A true IN2014DN08721A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-05-22 |
Family
ID=49483948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8721DEN2014 IN2014DN08721A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-04-27 | 2013-04-26 |
Country Status (13)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143138T3 (da) * | 2014-05-13 | 2022-04-25 | Bioatla Inc | Betinget aktive biologiske proteiner |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| EA201892063A1 (ru) * | 2016-03-14 | 2019-04-30 | Юниверситетет И Осло | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| KR102521276B1 (ko) * | 2018-10-31 | 2023-04-12 | 바이오아트라, 인코퍼레이티드 | 항-ctla4 항체, 항체 단편, 이들의 면역접합체 및 그 용도 |
| SG11202106478UA (en) * | 2019-01-03 | 2021-07-29 | Invetx Inc | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
| JP7620560B2 (ja) | 2019-03-08 | 2025-01-23 | オブシディアン セラピューティクス， インコーポレイテッド | 調整可能な制御のためのヒトカルボニックアンヒドラーゼ２組成物及び方法 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2021030303A1 (en) | 2019-08-12 | 2021-02-18 | Voyager Therapeutics, Inc. | High-sensitivity immunoassay for the detection of frataxin in biofluids |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| TW202208416A (zh) * | 2020-05-21 | 2022-03-01 | 印度商卡地拉保健有限公司 | Ｆｃ變體及其製備 |
| EP4139002A2 (en) | 2020-05-22 | 2023-03-01 | Formycon AG | Ace2-fc fusion proteins and uses thereof |
| CA3193930A1 (en) | 2020-10-29 | 2022-05-05 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| AU2022230745A1 (en) | 2021-03-03 | 2023-08-17 | Formycon Ag | Formulations of ace2 fc fusion proteins |
| US20250027067A1 (en) | 2021-11-24 | 2025-01-23 | Formycon Ag | Improved ace2 fusion proteins |
| WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
| EP4386084A1 (en) | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004035752A2 (en) * | 2002-10-15 | 2004-04-29 | Protein Design Labs, Inc. | ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS |
| AU2003280247A1 (en) | 2002-11-05 | 2004-06-07 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| EP1587540B1 (en) * | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005037867A1 (en) | 2003-10-15 | 2005-04-28 | Pdl Biopharma, Inc. | ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG |
| JP2008504002A (ja) * | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法 |
| CN101189028B (zh) * | 2004-07-12 | 2013-05-29 | 马克罗基因公司 | 具有变异Fc区的抗体的鉴定和工程化以及使用方法 |
| EP3342782B1 (en) * | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20110123440A1 (en) * | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| PL2573114T3 (pl) | 2005-08-10 | 2016-10-31 | Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania | |
| CA2625619A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Inc. | Cell display of antibody libraries |
| ES2742268T3 (es) * | 2007-12-26 | 2020-02-13 | Xencor Inc | Variantes de Fc con unión alterada a FcRn |
| CA2726845C (en) * | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| US20120100140A1 (en) | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
| SMT202100250T1 (it) | 2009-06-26 | 2021-07-12 | Regeneron Pharma | Anticorpi bispecifici facilmente isolati con formato di immunoglobulina nativo |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| BR112013002578A2 (pt) * | 2010-08-03 | 2019-05-14 | Abbvie Inc. | imunoglobinas de domínio variável duplo e usos das mesmas |
| US8483058B2 (en) | 2010-08-17 | 2013-07-09 | Qualcomm Incorporated | Systems and methods for traffic policing |
| CN103648748B (zh) | 2011-07-15 | 2016-03-16 | 巴塞尔聚烯烃意大利有限责任公司 | 包含丙烯与1-己烯的无规共聚物的聚烯烃带 |
| SG10202102283TA (en) * | 2011-09-30 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Ion concentration-dependent binding molecule library |
| WO2013109279A2 (en) * | 2012-01-19 | 2013-07-25 | Therapeutic Proteins Inc. | Stabilization of the anti-cd20 antibody rituximab |
-
2013
- 2013-04-26 EP EP13781110.5A patent/EP2841458A4/en not_active Withdrawn
- 2013-04-26 CN CN201380022401.0A patent/CN104428317B/zh active Active
- 2013-04-26 KR KR1020207009090A patent/KR20200037434A/ko not_active Ceased
- 2013-04-26 WO PCT/US2013/038538 patent/WO2013163630A1/en active IP Right Grant
- 2013-04-26 EP EP18209149.6A patent/EP3470433A1/en active Pending
- 2013-04-26 BR BR112014026740-5A patent/BR112014026740B1/pt active IP Right Grant
- 2013-04-26 HK HK15108290.3A patent/HK1207654A1/xx unknown
- 2013-04-26 US US14/396,851 patent/US20150065690A1/en not_active Abandoned
- 2013-04-26 IN IN8721DEN2014 patent/IN2014DN08721A/en unknown
- 2013-04-26 CA CA2871807A patent/CA2871807C/en active Active
- 2013-04-26 MX MX2014012978A patent/MX360368B/es active IP Right Grant
- 2013-04-26 JP JP2015509206A patent/JP6470170B2/ja active Active
- 2013-04-26 MX MX2018001914A patent/MX382840B/es unknown
- 2013-04-26 AU AU2013251309A patent/AU2013251309B2/en active Active
- 2013-04-26 RU RU2014147741A patent/RU2014147741A/ru unknown
- 2013-04-26 KR KR1020147030719A patent/KR20150008082A/ko not_active Ceased
-
2017
- 2017-09-08 AU AU2017225111A patent/AU2017225111B2/en active Active
-
2018
- 2018-03-02 US US15/910,588 patent/US10954288B2/en active Active
-
2019
- 2019-04-01 AU AU2019202229A patent/AU2019202229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013251309B2 (en) | 2017-06-22 |
| KR20200037434A (ko) | 2020-04-08 |
| US20150065690A1 (en) | 2015-03-05 |
| EP2841458A1 (en) | 2015-03-04 |
| US10954288B2 (en) | 2021-03-23 |
| CN104428317B (zh) | 2018-08-28 |
| KR20150008082A (ko) | 2015-01-21 |
| JP6470170B2 (ja) | 2019-02-13 |
| AU2019202229A1 (en) | 2019-04-18 |
| AU2013251309A1 (en) | 2014-10-30 |
| RU2014147741A (ru) | 2016-06-20 |
| HK1207654A1 (en) | 2016-02-05 |
| BR112014026740A2 (pt) | 2017-06-27 |
| US20180186863A1 (en) | 2018-07-05 |
| WO2013163630A1 (en) | 2013-10-31 |
| EP3470433A1 (en) | 2019-04-17 |
| JP2015515497A (ja) | 2015-05-28 |
| EP2841458A4 (en) | 2015-09-16 |
| CA2871807C (en) | 2022-10-04 |
| AU2017225111B2 (en) | 2019-01-03 |
| CN104428317A (zh) | 2015-03-18 |
| MX2014012978A (es) | 2015-02-05 |
| AU2017225111A1 (en) | 2017-09-28 |
| AU2019202229B2 (en) | 2021-02-11 |
| BR112014026740B1 (pt) | 2022-10-04 |
| MX360368B (es) | 2018-10-29 |
| MX382840B (es) | 2025-03-13 |
| CA2871807A1 (en) | 2013-10-31 |
| BR112014026740A8 (pt) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN08721A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX2022000026A (es) | Anticuerpos para tau. | |
| MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
| PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
| PH12015502565A1 (en) | Anti-transferrin receptor antibodies and methods of use | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| IN2014DN05885A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| MX2020011064A (es) | Inmunoglobulinas heterodimericas. | |
| MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| PH12014500841B1 (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE | |
| PH12012501493A1 (en) | Anticoagulant antidotes | |
| MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
| MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
| MX381841B (es) | Anticuerpos anti-jagged y métodos de uso. | |
| TN2013000388A1 (en) | Anticoagulant antidotes | |
| MX353951B (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
| UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
| MX2015010789A (es) | Anticuerpos anti-pcsm. | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| AU345983S (en) | Cosmetic cases and cosmetic kits | |
| UA106373C2 (ru) | Применение поллентара как средства фригопротекторного действия |